YOHIMBINE HC 10 MG / ML | 60ML

Yohimbine, also known as quebrachine, is an inhibitor of the α2-adrenergic receptor. It is alkaloid in nature and is derived from Pausinystalia Yohimbe and Rauwolfia serpentina. Its history dates back to 1934 when it was discovered by an American botanist named R. Raymond Hamet from several herb species. It has been used as an aphrodisiac in folk medicine. Furthermore, research shows that it exhibits a cardioprotective effect, promotes weight loss and might prove helpful in the treatment of cancer. At Pinnacle Peptides, yohimbine for sale is exclusively available for research and experimentation.

From Pubchem

IUPAC Name: (1S,15R,18S,19R,20S)-18-hydroxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate
Synonyms: Yohimbin, Quebrachin, Quebrachine
Molecular Formula: C21H26N2O3
Molecular Weight: 354.4 g/mol
CAS number: 146-48-5
PubChem CID: 8969

Yohimbine’s exact mechanism of action is unknown. However, research indicates that it acts as an antagonist at the α2-adrenergic receptor located on the presynaptic nerves. It selectively binds to α2 receptors and has shown low affinity towards α1 receptors. Blockage of these receptors enhances sympathetic nerve stimulation and norepinephrine levels in the blood.

Furthermore, it stimulates the release of NO which promotes vasodilation and increases blood flow to the penis, resulting in erection. Studies show that yohimbine also exhibits some activity at dopaminergic and serotonin receptors.

1. Blood Clotting

α2-adrenergic receptors play an important role in the regulation of blood clotting. Since yohimbine has been shown to block these receptors, it might help prevent the onset of stroke and myocardial infarction in patients with low INR values. One study on healthy individuals found that the minimum effective dose of yohimbine to inhibit platelet aggregation was 8 mg. This particular effect lasted 12 hours when a 12mg dose was administered [1]. Furthermore, research shows that it can prevent orthostatic-induced platelet aggregation, thus it might reduce the risk of thrombotic vascular events in patients with atherosclerosis [2].

2. Cancer

Research shows that epinephrine and norepinephrine stimulate the physiological processes that promote cell proliferation in cancer cells. Furthermore, G protein-coupled receptors, including α2-adrenergic receptors, are associated with various forms of cancer.

Yohimbine exhibits antagonist action at these receptors and might slow down the progression of cancer. One study found that Yohimbine’s derivative, Y7, can block the vasopressin and oxytocin receptors that are associated with prostate and lung cancer [3, 4]. Moreover, it has been shown that administration of yohimbine lowers the levels of PSA and steroid 5-α reductase, thus indicating that it might be effective for the treatment of benign prostatic hyperplasia [5].

3. Sexual dysfunction

A dose escalation study was designed to demonstrate the safety and efficacy of yohimbine in men with hypertension. It found that yohimbine resulted in a 100% erectile response among responders, with a more pronounced effect observed in non-smokers and individuals with less severe erectile dysfunction [6]. In a rat study, it was proposed that yohimbine exerts its effects on the spinal level by acting on both α1 and α2 adrenergic receptors [7].

4. Myocardial Dysfunction

Research indicates that inhibition of α2 adrenergic receptors can mitigate septic cardiomyopathy by suppressing endothelial activation [8]. Furthermore, yohimbine has been shown to reverse the LPS-induced reduction in left ventricular ejection fraction, stroke volume, and cardiac output in rats [9]. Similarly, another study suggests that pretreatment with yohimbine, in combination with berberine, may prevent LPS-induced myocardial infarction. This protective effect is attributed to the inhibition of myocardial apoptosis and the reduction of nitric oxide production [10].

5. Weight loss

One study was designed to investigate the effect of yohimbine on weight loss in rat model of obesity. The results found that it reduced appetite, improved lipid profiles and decreased adipose tissue fat [11]. The weight loss effects of yohimbine were further confirmed by a study in athletes where yohimbine administration resulted in a significant reduction in fat mass as compared to the control [12].

Yohimbine is an alkaloid derived from the herb species. It is an antagonist of the α2 adrenergic receptor located at the presynaptic nerve. It has been shown to improve sexual function and reduce the risk of cancer. Animal studies indicate that it reduces the consequences associated with myocardial infarction. Furthermore, it has been shown to promote weight loss. It has not been approved by the FDA yet. We don’t support its unwarranted use and offer yohimbine purchase exclusively for research and experimentation. Only buy Yohimbine if you are a licensed researcher.

1. Berlin, I., et al., The alpha 2-adrenergic receptor antagonist yohimbine inhibits epinephrine-induced platelet aggregation in healthy subjects. Clin Pharmacol Ther, 1991. 49(4): p. 362-9.
2. Andrews, N.P., D.S. Goldstein, and A.A. Quyyumi, Effect of systemic alpha-2 adrenergic blockade on the morning increase in platelet aggregation in normal subjects. Am J Cardiol, 1999. 84(3): p. 316-20.
3. Zhong, M., et al., Oxytocin induces the migration of prostate cancer cells: involvement of the Gi-coupled signaling pathway. Mol Cancer Res, 2010. 8(8): p. 1164-72.
4. Paciaroni, N.G., et al., Yohimbine as a Starting Point to Access Diverse Natural Product-Like Agents with Re-programmed Activities against Cancer-Relevant GPCR Targets. Bioorg Med Chem, 2020. 28(14): p. 115546.
5. Zhao, Y., et al., Yohimbine hydrochloride inhibits benign prostatic hyperplasia by downregulating steroid 5α-reductase type 2. Eur J Pharmacol, 2021. 908: p. 174334.
6. Guay, A.T., et al., Yohimbine treatment of organic erectile dysfunction in a dose-escalation trial. Int J Impot Res, 2002. 14(1): p. 25-31.
7. Carro-Juáreza, M. and G. Rodríguez-Manzo, Yohimbine reverses the exhaustion of the coital reflex in spinal male rats. Behav Brain Res, 2003. 141(1): p. 43-50.
8. Yu, X., et al., α(2A)-adrenergic blockade attenuates septic cardiomyopathy by increasing cardiac norepinephrine concentration and inhibiting cardiac endothelial activation. Sci Rep, 2018. 8(1): p. 5478.
9. Wang, Y., et al., Yohimbine promotes cardiac NE release and prevents LPS-induced cardiac dysfunction via blockade of the presynaptic α2A-adrenergic receptor. PLoS One, 2013. 8(5): p. e63622.
10. Wang, Y.Y., et al., Pretreatment with berberine and yohimbine protects against LPS-induced myocardial dysfunction via inhibition of cardiac I-[kappa]B[alpha] phosphorylation and apoptosis in mice. Shock, 2011. 35(3): p. 322-8.
11. Dudek, M., et al., A Comparison of the Anorectic Effect and Safety of the Alpha2-Adrenoceptor Ligands Guanfacine and Yohimbine in Rats with Diet-Induced Obesity. PLoS One, 2015. 10(10): p. e0141327.
12. Ostojic, S.M., Yohimbine: the effects on body composition and exercise performance in soccer players. Res Sports Med, 2006. 14(4): p. 289-99.